D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other equities analysts have also issued reports about the company. TD Cowen reduced their price objective on Humacyte from $5.00 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Barclays began coverage on shares of Humacyte in a research report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price target for the company. HC Wainwright decreased their price objective on Humacyte from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Finally, Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, August 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of “Moderate Buy” and an average target price of $9.29.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $1.79 on Tuesday. The company’s fifty day moving average price is $1.79 and its 200-day moving average price is $1.99. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The firm has a market capitalization of $283.49 million, a price-to-earnings ratio of -3.98 and a beta of 1.89. Humacyte has a one year low of $1.15 and a one year high of $6.77.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.94 million. On average, equities research analysts anticipate that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Activity at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 591,685 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 591,685 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,482,090 shares of company stock valued at $7,466,382. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently modified their holdings of the stock. Heights Capital Management Inc. bought a new stake in shares of Humacyte during the 1st quarter valued at about $6,863,000. Woodline Partners LP raised its stake in Humacyte by 38.7% in the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock worth $6,735,000 after buying an additional 1,101,198 shares in the last quarter. CenterBook Partners LP lifted its holdings in Humacyte by 141.1% in the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock worth $7,169,000 after buying an additional 2,007,743 shares during the period. RA Capital Management L.P. bought a new stake in Humacyte during the 1st quarter valued at approximately $5,648,000. Finally, Geode Capital Management LLC boosted its position in Humacyte by 33.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after acquiring an additional 738,142 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.